Immunomodulatory interventions in myocardial infarction and heart failure: a systematic review of clinical trials and meta-analysis of IL-1 inhibition

Mona Panahi1, Angelos Papanikolaou1, Azam Torabi2, Ji-Gang Zhang3, Habib Khan2, Ali Vazir2, Muneer G. Hasham3, John G.F. Cleland1,2, Nadia A. Rosenthal1,3, Sian E. Harding1, and Susanne Sattler1*

1National Heart and Lung Institute, Imperial College London, Du Cane Road, London W12 0NN, UK; 2Royal Brompton Hospital, Royal Brompton and Harefield NHS Foundation Trust, Sydney Street, London SW3 6NP, UK; and 3The Jackson Laboratory, 600 Main Street, Bar Harbor, ME 04609, USA

Received 9 April 2018; revised 26 May 2018; editorial decision 11 June 2018; accepted 18 June 2018

Abstract
Following a myocardial infarction (MI), the immune system helps to repair ischaemic damage and restore tissue integrity, but excessive inflammation has been implicated in adverse cardiac remodelling and development towards heart failure (HF). Pre-clinical studies suggest that timely resolution of inflammation may help prevent HF development and progression. Therapeutic attempts to prevent excessive post-MI inflammation in patients have included pharmacological interventions ranging from broad immunosuppression to immunomodulatory approaches targeting specific cell types or factors with the aim to maintain beneficial aspects of the early post-MI immune response. These include the blockade of early initiators of inflammation including reactive oxygen species and complement, inhibition of mast cell degranulation and leucocyte infiltration, blockade of inflammatory cytokines, and inhibition of adaptive B and T-lymphocytes. Herein, we provide a systematic review on post-MI immunomodulation trials and a meta-analysis of studies targeting the inflammatory cytokine Interleukin-1. Despite an enormous effort into a significant number of clinical trials on a variety of targets, a striking heterogeneity in study population, timing and type of treatment, and highly variable endpoints limits the possibility for meaningful meta-analyses. To conclude, we highlight critical considerations for future studies including (i) the therapeutic window of opportunity, (ii) immunological effects of routine post-MI medication, (iii) stratification of the highly diverse post-MI patient population, (iv) the potential benefits of combining immunomodulatory with regenerative therapies, and at last (v) the potential side effects of immunotherapies.

Keyword
Immunomodulation • Immunotherapy • Myocardial infarction • Heart failure • IL-1 inhibition • Systematic review

1. Introduction
Ischaemic heart disease is estimated to account for 9 million deaths per year and is the leading cause of global mortality.1 Importantly, 63% of myocardial infarction (MI) patients in the UK develop heart failure (HF) within 6 years2 and ~90% of mortality post-MI occurs after the development of HF.3

The immune system is involved both in events leading up to an MI and in post-MI processes and development towards HF. High levels of systemic inflammation due to metabolic or immunological conditions contribute significantly to an increased risk of cardiovascular disease.4,5 Post-MI, the severe tissue damage caused by an acute infarct is a potent trigger to activate the immune system, which orchestrates the various steps of the post-MI healing process, starting immediately with the removal of cellular debris and restoration of tissue integrity. A tightly controlled balance between inflammatory and regulatory mechanisms is essential, because an inefficient early immune response may lead to fatal cardiac rupture, while excessive inflammation may cause collateral damage to healthy tissue, making both situations detrimental to healing. Once acute inflammation has been cleared, development towards HF may still be exacerbated by a persistent autoimmune-inflammatory condition which maintains low levels of tissue damage sustaining cardiomyocyte loss, fibrosis, and pathological ventricular remodelling.6

---

* Corresponding author. Tel: +44 (0)20 759 42737; E-mail: s.sattler@imperial.ac.uk
© The Author(s) 2018. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
The clinical relevance of both pre- and post-MI inflammation has been recognized for several decades and a wide variety of clinical trials have attempted to target the immune system, with the majority investigating effects on acute patient survival at a time when the immune response is most evident. With an increased understanding of long-term immunological effects pre- and post-MI, there is growing interest in targeting the immune system to prevent MI and HF. An immense and extensively reviewed body of pre-clinical research supports the hypothesis that blocking excessive inflammation has beneficial effects on MI prevention and post-MI HF development, yet outcomes of clinical trials to date have been varied and inconclusive as reviewed below.

In this review, we aim to provide a comprehensive overview of clinical trials on pharmacological interventions targeting the immune system to prevent MI or improve post-MI prognosis, from broad immunosuppressive therapy to more refined approaches targeting specific pathways and factors including reactive oxygen species (ROS), complement, mast cells, leucocyte infiltration, inflammatory cytokines interleukin (IL)-1, tumour necrosis factor (TNF), and IL-6, and the inhibition of adaptive B and T lymphocytes. Notably, most of these therapeutics are repurposed anti-inflammatory and immunosuppressive agents that have been in long-standing clinical use to prevent transplant rejection or treat autoimmunity.

The clinical relevance of both pre- and post-MI inflammation has been recognized for several decades and a wide variety of clinical trials have attempted to target the immune system, with the majority investigating effects on acute patient survival at a time when the immune response is most evident. With an increased understanding of long-term immunological effects pre- and post-MI, there is growing interest in targeting the immune system to prevent MI and HF. An immense and extensively reviewed body of pre-clinical research supports the hypothesis that blocking excessive inflammation has beneficial effects on MI prevention and post-MI HF development, yet outcomes of clinical trials to date have been varied and inconclusive as reviewed below.

In this review, we aim to provide a comprehensive overview of clinical trials on pharmacological interventions targeting the immune system to prevent MI or improve post-MI prognosis, from broad immunosuppressive therapy to more refined approaches targeting specific pathways and factors including reactive oxygen species (ROS), complement, mast cells, leucocyte infiltration, inflammatory cytokines interleukin (IL)-1, tumour necrosis factor (TNF), and IL-6, and the inhibition of adaptive B and T lymphocytes. Notably, most of these therapeutics are repurposed anti-inflammatory and immunosuppressive agents that have been in long-standing clinical use to prevent transplant rejection or treat autoimmunity.

2. Systematic search strategy and meta-analysis methods

A literature search was performed using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Meta-analysis on selected trials implemented the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) tool endorsed by the Cochrane collaboration. The review protocol was prospectively registered in PROSPERO. Briefly, a systematic literature search on immune modulatory trials in MI, HF, and acute coronary syndrome (ACS) patients including a proportion of ischaemia patients, was conducted using PubMed and clinicaltrials.gov. Search terms ‘myocardial infarction’, ‘ventricular remodelling’, ‘ischaemia reperfusion’, and ‘heart failure’ were combined with interventions using simple Boolean operators. Placebo-controlled clinical trials published in the last 50 years, written in English and available as full text online were included in our review.

Despite a wide range of therapeutic strategies, only clinical trials using IL-1 antagonists have been independently repeated in a way allowing comparison and were selected for meta-analysis to assess treatment efficacy. As shown in Figure 2, a total of 168 studies were identified, but only six studies met the above inclusion criteria for qualitative analysis. The Cochrane risk of bias tool was used for...
the identification of any systematic error or interferences in results to be highlighted. The primary outcome measure analysed was major adverse cardiac events (MACE), which included mortality, incidence of HF, respiratory failure, and acute kidney injury and was reported in three out of six studies. For meta-analyses, results from the three included study were pooled into MedCalc Version 17.5.312 and used to calculate the risk ratios between intervention and placebo, create forest plots, and assess the quality of evidence. The random effects model was implemented using the Dersimonian Laird method.13 Random effects models (as opposed to fixed effect models) do not assume one common treatment effect between trials, but each included trial may have a different treatment effect, and they therefore, take into account variance within trials and between trials.14

3. The post-MI immune response as therapeutic target: from full-blown suppression to targeting specific pathways

Attempts to target the post-MI immune response in clinical trials were first made in the 1960s. Our understanding of the diverse roles of the immune system in tissue homeostasis and the multi-dimensional crosstalk between the immune and the cardiovascular system has increased significantly since that time. An extensive body of pre-clinical research has started to unravel the complex, tightly controlled temporal, and spatial interplay between immune cells and factors in events leading up to MI as well as post-MI,7,15 and it is now appreciated that targeted approaches blocking specific detrimental pathways while maintaining beneficial responses, may be the way forward instead of broad immunosuppression.

3.1 Broad-spectrum immunosuppression

Early trials directed at the post-MI immune response used strong broad-spectrum immunosuppressive drugs including corticosteroids, methotrexate, cyclosporin A (CsA), or intravenous immunoglobulin (IVIg). This was based on the hypothesis that all inflammation was detrimental for post-MI recovery.16 Table 1 compares study characteristics of clinical trials using broadly immunosuppressive treatment post-MI.

3.1.1 Corticosteroids

Corticosteroids are well-established clinical use to treat inflammatory conditions such as allergies and autoimmunity. Their use post-MI was expected to be beneficial, due to their overall suppressive effect on the recruitment and activation of both innate and adaptive immune cells.30 However, despite pre-clinical and clinical research for over 50 years, evidence concerning the efficacy of corticosteroids after MI is still conflicting.

A previous systematic review with meta-analysis assessed corticosteroid use in 2646 patients with acute MI (AMI) in 11 trials from 1964 to 1989.16 Although corticosteroids decreased mortality by 26% compared to placebo, this did not seem to stem from a cardio-protective effect, as infarct size or myocardial rupture rates were unchanged. Meta-analysis findings were limited, as most included studies were small (>40 patients) and little information regarding protocol and measurements had been provided. Furthermore, very short follow-up periods (median 24.5 days) limited the possibility to assess any effects on development of post-MI HF.

More recent results of subsequent corticosteroid trials are still conflicting, but due to high diversity in study populations, the varied nature of clinical endpoints and different follow-up periods, meaningful comparisons are hard to draw. However, overall mortality was reported to be
| Study | Design | Intervention | Follow-up | Outcome measures |
|-------|--------|--------------|-----------|------------------|
| **Corticosteroids** | | | | |
| Donnino et al. | R, DB, PC | Corticosteroids | 7 days | |
| Liu and Liu | COP:ADHF | | 19 months | |
| Mentzelopoulos et al. | R, DB, PC | | 2 months | |
| Tsai et al. | R, DL, PC | | 7 days | |
| Giugliano et al. | Madias (1982) | | 6 months | |
| Henning (1981) | R, DB, PC | | 2 days | |
| Peters (1978) | R, DB, PC | | 70 h | |
| Barzilai (1972) | NR, OL, PC | | 3 weeks | |
| **Methotrexate** | | | | |
| Moreira et al. | TETHYS | Methotrexate | 3 months | |
| Everett et al. | CIRT | Methotrexate | 3-5 years | |
| Moreira et al. | METIS | Methotrexate | 3 months | |
| Gong et al. | R, SB, PC | Methotrexate | 3 months | |
| **Cyclosporine A** | | | | |
| Hausenloy et al. | R, DB, PC | | 3 months | |
| Charr et al. | R, SB, PC | | 1 year | |
| Yanghong et al. | CYCLE | | 6 months | |
| Ota et al. | R, OL, PC | | 6 months | |
| Cung (2015) | AMI (STEMI) | | 6 months | |
| Ghaffari (2013) | STEMI | | 6 months | |

Table 1: Study characteristics of clinical trials using broad immunosuppression post-MI

**Note:** Concomitant use of vasopressors was not reported in all studies.

- **Study population**:
  - MI: Myocardial Infarction
  - CHF: Congestive Heart Failure
  - Acute MI: Acute Myocardial Infarction
  - STEMI: ST-elevation Myocardial Infarction

- **Intervention Dose/administration**:
  - D, P: Daily, Per oral
  - 24 mg/kg IV: 24 mg/kg administered intravenously
  - 0.05 mg/kg/h: 0.05 mg/kg/hour administered intravenously
  - 0.05 mg/kg + 0.05 mg/kg/h: 0.05 mg/kg + 0.05 mg/kg/hour administered intravenously

- **Follow-up**:
  - 7 days
  - 19 months
  - 2 months
  - 70 h
  - 3 weeks
  - 3 months
  - 3-5 years
  - 6 months
  - 1 year

- **Outcome measures**:
  - Mortality
  - Cardiac arrest
  - Neurological outcome
  - Shock reversal
  - Mean arterial pressure
  - Urine output
  - Serum creatinine
  - ECG changes
  - Infarct size
  - LVEF
  - CK-MB
  - cTnT
  - CRP
  - MCP-1
  - TNF-α
  - Hs-TNT
  - hs-TNT
  - QOL score
  - LDL-NA
  - AMI
  - TIMI
  - MACE
  - NPY
  - LVEF
  - LVAD
  - LVSD
  - LVEF
  - MACE
  - LVEDV
  - LVESV
  - LVEDD
  - NYHA
  - 6MWT
  - QOL score
  - CRP
  - sICAM-1
  - sIL-1RA
  - IL-10
  - IL-16
  - TNF-α

- **Adverse Events**:
  - Hypertension
  - Hyperglycemia
  - Hypertriglyceridemia
  - Hypercholesterolemia
  - Atrioventricular block
  - Congestive heart failure
  - Diarrhea
  - Nausea
  - Myelosuppression
  - Transaminitis
  - Overall mortality

**Continued**
Post-MI immunomodulation: a systematic review

3.1 Methotrexate

Methotrexate is another immunosuppressive drug commonly used in clinical practice for the treatment of rheumatoid arthritis. Its mechanism of action involves the release of endogenous adenosine, and suppression of innate inflammation and the adaptive immune response.\(^{23}\) The addition of methotrexate to conventional chronic HF (CHF) therapy was supported by a small trial by Gong et al.\(^{24}\) in 2006 including 71 patients who received either a 7.5 mg weekly dose of methotrexate or placebo over a 12 week period. This improved patients’ inflammatory profile including levels of IL-6, TNF, monocyte chemoattractantprotein-1, and C-reactive protein (CRP). New York Heart Association (NYHA) functional group, quality of life and 6 min walk test (6MWT) distance when compared with placebo. Conversely, the METIS trial (2009) using a similar treatment regime in CHF patients found no improvement in 6MWT or CRP, and although a trend was shown towards improved the NYHA group, differences were not significant.\(^{23}\) The TETHYS trial of methotrexate (2017) in 84 ST-Elevation MI (STEMI) patients on the other hand showed worsened left ventricular ejection fraction (LVEF) and no reduction in infarct size at 3 months follow-up compared with the placebo group.\(^{21}\)

Low-dose methotrexate is currently also being tested for its usefulness in the prevention of cardiovascular morbidity and mortality in 7000 patients with prior MI and Type 2 diabetes or metabolic syndrome (Cardiovascular Inflammation Reduction Trial, CIRT).\(^{22}\) CIRT aims to test the inflammatory hypothesis of atherothrombosis, which suggests that inhibition of inflammation may reduce atherothrombosis and thus prevent occurrence of adverse cardiovascular events.

3.1.3 Cyclosporin A

CsA inhibits antigen presentation by dendritic cells and effector T lymphocyte function and has been in long-standing clinical use as immunosuppressant to block transplant rejection.\(^{24}\) Notably, however, use of CsA post-MI was attempted due to its ability to protect cardiomyocytes from cell death due to ischaemia/reperfusion injury (IRI). This cardio-protective function of CsA stems from its ability to inhibit the opening of the mitochondrial permeability transition pore (mPTP) and thereby prevent necrotic cell death.\(^{25}\) A meta-analysis by Yingzhong et al.\(^{26}\) assessed the use of CsA in five randomized control trials of AMI and decreased in only two out of four studies performed since publication of the previous meta-analysis. Importantly, decreased mortality was reported in trials with slightly longer follow-up periods, while acute studies fail to show improvement. The COPE-ADHF trial (2013) reported significant improvement in mortality with dexamethasone followed by prednisolone treatment for 7 days in acute decompensated HF (27% AMI). This benefit persisted over the follow up period of 1–36 months, and the number of deaths was three in the steroid as compared with 10 in the placebo group.\(^{18}\) A hydrocortisone trial by Tsai et al.\(^{20}\) in 97 non-randomized cardiac arrest patients also improved haemodynamics by 40%, without increased survival rates. A similar trial by Mentzelopoulos et al.\(^{19}\) in which cardiac arrest patients were administered methylprednisolone during cardiopulmonary resuscitation followed by hydrocortisone, showed increased survival until hospital discharge, and improved haemodynamics and organ function during a 1 year follow-up. However, hydrocortisone did not affect cardiac shock reversal or mortality rates in another randomized control trial by Donnino et al.\(^{17}\) with 50 cardiac arrest patients.
was no difference between the IVIg and the placebo groups.28

However, when the same team repeated this treatment in 62 patients with AMI following percutaneous coronary intervention (PCI), there was no difference between the IVIg and the placebo groups.29

6 months follow-up, IVIg significantly up-regulated the anti-inflammatory cytokine profile and increased LVEF by 5% compared with baseline.30

CHF, 23 of which suffered from post-ischaemic damage, and LVEF was <40%. Patients received either IVIg or placebo for 21 weeks. At 6 months follow-up, IVIg significantly up-regulated the anti-inflammatory cytokine profile and increased LVEF by 5% compared with baseline. However, when the same team repeated this treatment in 62 patients with AMI following percutaneous coronary intervention (PCI), there was no difference between the IVIg and the placebo groups.30

In summary, although broad immunosuppression by corticosteroids, methotrexate, CsA, and IVIg are widely accepted in clinical practice as gold-standard anti-inflammatory and immunosuppressive therapies, their use immediately following MI remains controversial. Beneficial effects in clinical trials are inconsistent and some studies suggest detrimental effects on the immune system.

3.1.4 IVIg

IVIg is intravenously administered immunoglobulin G obtained from pooled donor plasma. It binds to and neutralizes components of the immune system which could otherwise instigate downstream inflammatory effects. This includes necrotic debris, danger-associated molecular patterns (DAMPs), complement, integrins, cytokines, and leucocyte receptors.34

IVIg is used clinically in a range of immunological and inflammatory diseases, either as replacement therapy for antibody deficiencies or as immunosuppressive for inflammatory/autoimmune conditions.35

A potentially beneficial effect of IVIg in the context of cardiovascular disease was first tested by Gullestad et al. in 40 patients with stable CHF, 23 of which suffered from post-ischaemic damage, and LVEF was <40%. Patients received either IVIg or placebo for 21 weeks. At 6 months follow-up, IVIg significantly up-regulated the anti-inflammatory cytokine profile and increased LVEF by 5% compared with baseline. However, when the same team repeated this treatment in 62 patients with AMI following percutaneous coronary intervention (PCI), there was no difference between the IVIg and the placebo groups.30

In summary, although broad immunosuppression by corticosteroids, methotrexate, CsA, and IVIg are widely accepted in clinical practice as gold-standard anti-inflammatory and immunosuppressive therapies, their use immediately following MI remains controversial. Beneficial effects in clinical trials are inconsistent and some studies suggest detrimental effects on the immune system, causing concerns about a large risk-benefit ratio.36,37 Importantly, curative or prophylactic effects of CsA treatment on the adaptive immune response and development of HF would be informative.

3.2 Targeting selected pathways to achieve immunomodulation

Recently, our understanding of the complexity of immune pathways involved in early repair as well as long-term pathogenesis after MI has improved significantly. The necessity of early acute inflammation and the need for a balanced and co-ordinated response for successful healing and functional recovery are now being appreciated. A wide range of studies have therefore aimed to target individual pathways to modulate the immune response towards regeneration instead of fully suppressing the immune system.

3.2.1 Immediate post-ischaemic events

Acute I/R injury immediately after infarct is mediated by the production of ROS and mitochondrial dysfunction which causes necrotic cell death and the release of DAMPs. DAMPs are intracellular molecules passively released during myocardial necrosis and fragments of the extracellular matrix. They include prominent examples such as hyaluronic fragments, high-mobility group box 1, heat-shock proteins, and act as potent inflammatory activators for most cell types including cardiomyocytes, fibroblasts, endothelial cells, and immune cells.15 DAMPs can trigger expression of pro-inflammatory cytokines and pro-hypertrophic proteins, initiate cell death pathways, promote endothelial dysfunction, and induce fibrosis.38 So far, clinical trials aiming at events immediately after MI have targeted early inflammatory mediators such as mitochondrial damage, as discussed above, ROS, and the complement system (Table 2).

ROS. ROS are highly reactive chemical compounds including peroxides, superoxide, and nitric oxide, which promote leucocyte recruitment into the damaged tissue and cause further oxidative stress, resulting in more macromolecular damage.67 This supports the use of anti-oxidants such as N-acetylcysteine (NAC) to block ROS post-MI66 and evidence of beneficial effects of NAC was first demonstrated in a small trial in 27 MI patients by Arstall et al.12 Although no functional changes were established by echocardiography, significantly less oxidative stress was observed in NAC treated patients. In two other early trials with small study populations, ISLAND (1996) and Yesilbursa et al.,40,41 NAC treatment improved LV function and reduced oxidative stress post-MI. Benefits of NAC use were confirmed by the NACIAM (2017) trial of 112 STEMI patients undergoing PCI, which received NAC and nitrate therapy. On cardiac magnetic resonance imaging (cMRI), high-dose NAC doubled myocardial salvage from 27% to 60% and an absolute reduction in infarct size by 5.5% compared with placebo was observed.39 However, it is impossible to speculate about the long-term effects of this intervention, as patients were observed only 7 days after treatment.

Decades of research and several small clinical trials now provide a promising base for a large randomized multi-center study, to finally answer the question if NAC treatment is a beneficial agent to reduce reperfusion injury after MI. If designed with long-term effects in mind, benefits related to HF development may be assessed as well. Importantly, when interpreting NAC trial results, it also needs to be considered that anti-oxidants affect other molecular pathways too and beneficial effects may not be due to immunological effects only.49

Complement. The complement system is part of innate immunity and a complex network of proteins in the blood responsible for clearance of microbes and damaged cells. Upon reperfusion of occluded vessels, tissue damage triggers complement activation leading to inflammation, and additional tissue destruction. In particular, the classical complement...
| Study | Design | n  | Study population | Intervention | Dose/administration | Follow-up | Outcome measures |
|-------|--------|----|------------------|--------------|---------------------|-----------|------------------|
| **N-Acetylcysteine** | | | | | | | |
| Pasupathy et al. | R, DB, PC | 112 | STEMI | NAC (+ NTG) | 20 mg/min/1 h then 10 mg/min for 47 h (total 29 g over 2 days) | 3 months | EDV (0); ESV (0); Infarct size (++); LVEF (0); MVO (0); Myocardial salvage (+); SV (0); symptomatic (+) |
| Yesilbursa et al. | R, DB, PC | 22 | AMI | NAC (+ NTG+ streptokinase) | 15 g IV infused over 24 h | 3 months | DF (0); DT (0); E/A ratio (0); LVEDD (+); LVEF (+); LVESD (+); LVWMSI (+); SF (0); CK-MB (0); plasma MDA (+) |
| SOchman et al. | R, BU, PC | 30 | AMI | NAC (+ NTG + streptokinase) 1.5 milU + aspirin 200 mg + 2.5–5 mg midazolam | 100 mg/kg IV (50 mg/kg undiluted bolus; 50 mg/kg in 200 ml IV saline over 30 min) | 2 weeks | CK (+); ECG 0; LVEF (+); MACE (+); REF (+) |
| Arstall et al. | R, BU, NPC | 25 | AMI | NAC (+ NTG + streptokinase) | 15 g IV infused over 24 h | 7 days | ECG (0); LVEF (0); GSH (+), GSH/GSSG ratio (+), MDA (+). |

| Study | Design | n  | Study population | Intervention | Dose/administration | Follow-up | Outcome measures |
|-------|--------|----|------------------|--------------|---------------------|-----------|------------------|
| **Complement inhibitors** | | | | | | | |
| Fattouch et al. | R, DB, PC | 80 | STEMI | C1-INH | 1000 UI | 48 h | Mortality (0); CI; CVP (0); GRMK (-); MAP (-); MPAP (0); SV (+); PCWP (0); cTnI (+); PCR (0); SVR (0) |
| Thielmann et al. | R, OL, PC | 67 | STEMI | C1-INH | 40 IU/kg bolus + 20 IU/kg | 30 days | C3/C4 levels (+); cTnI (+) |
| Zwaan et al. | NR, OL, NPC | 22 | STEMI | C1-INH | 50 U/kg + 1.25 U/kg/h for 48 h OR 100 U/kg + 1.25 U/kg/h for 48 h | 3 days | C4 (+); CK-MB (+); cTnT (+) |
| Testa et al. | R, DB, PC | 5745 | STEMI | Pexelizumab | 2 mg/kg + 0.05 mg/kg per/h for 24/24 | 3 months | Mortality (0); MACE (0) |
| Investigators (2007) | | | | | | | |
| Smith (2006) | R, DB, PC | 4254 | Elective CABG | Pexelizumab | 2 mg/kg + 0.05 mg/kg/h for 24/24 | 6 months | Mortality (0); MACE (0); |
| Smith (2004) | R, DB, PC | 3099 | Elective CABG | Pexelizumab | 2 mg/kg + 0.05 mg/kg/h for 24/24 | 6 months | Mortality (+); MACE (+); CK-MB (+) |
| Mahaffey (2003) | R, DB, PC | 943 | STEMI | Pexelizumab | 2 mg/kg OR 2 mg/kg + 0.05 mg/kg/h for 20/24 | 6 months | Mortality (0); ECG (0); MACE (0); CK-MB (0) |
| Granger (2003) | R, DB, PC | 960 | STEMI | Pexelizumab | 2 mg/kg OR 2 mg/kg + 0.05 mg/kg/h for 20/24 | 6 months | Mortality (+); ECG (0); MACE (0); CK-MB (0) |
| Sherman (2004) | R, DB, PC | 914 | Elective CABG | Pexelizumab | 2 mg/kg OR 2 mg/kg + 0.05 mg/kg/h for 20/24 | 7 days | Mortality (0); composite score (0); ECG (0); MACE (0); future MI (+); LV dysfunction (0); CK-MB (0) |

C1-INH, complement 1 protein inhibitor; C3/C4, complement protein 3 and 4; CABG, coronary artery bypass graft; CI, cardiac index; CK, creatine kinase; CK-MB, creatine kinase-MB; cTnI, cardiac troponin I; cTnT, cardiac troponin T; DB, double blind; DF, diastolic flow; DT, deceleration time; E/A ratio, early atrial filling ratio; ECG, electrocardiogram; EDV, end-diastolic volume; ESV, end-systolic volume; GSH, glutathione; GSH/GSSG, glutathione/oxidized glutathione ratio (re-do x status); GRMK, global and regional myocardial kinesia; IV, intravenous; IVRT, isovolumic relaxation time; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; LVWMSI, left ventricular wall motion index score; MACE, major adverse cardiac event; MAP, mean arterial pressure; MDA, malondialdehyde; MI, myocardial infarction; MVO, microvascular obstruction; OL, open label; PC, placebo controlled; NAC, N-acetylcysteine; NPC, not placebo controlled; NR, non-randomized; NTG, nitroglycerin; PCWP, pulmonary capillary wedge pressure; R, randomized; REF, regional ejection fraction; SF, systolic flow; STEMI, ST-elevation myocardial infarction; SV, stroke volume; UI, international units; (þ), supports intervention use; (-), supports placebo use; (0), no difference between intervention and placebo.
pathway is activated and can be chronically sustained, which directly damages the myocardium.  

**C1:** The C1 proteins initiate the classical complement cascade. Inhibition of the C1 receptor using C1-INH in AMI patients given thrombolytic therapy showed decreased cTnT and Creatinine Kinase-MB (CK-MB) levels. In a study of 67 STEMI patients undergoing emergency CABG, Thielmann et al. showed that C1-INH significantly reduced 

Similarly, in 80 STEMI patients undergoing emergency CABG, Fattouch et al. described improvement in functional measures and overall survival. Cardiopulmonary bypass support, high-dose inotropes and time of intubation, intensive care unit stay, and hospital stay were all greatly reduced in the C1-INH group. Furthermore, these patients showed significantly improved mean arterial pressure, cardiac index, stroke volume, and cTnI levels.

**C5:** C5 is part of the classical complement cascade acting downstream of C1. A previous meta-analysis on clinical trials using pexelizumab, a monoclonal antibody against C5, showed no improvement in outcomes following MI, but reduced mortality in patient undergoing CABG.

Table 2 summarizes study characteristics of trials targeting early inflammation post-MI by blocking ROS and complement. Although more thorough studies are required to reach conclusive results, the above described clinical trials provide promising results that early post-MI events such as ROS- and complement-mediated damage may be potential targets to improve post-MI outcome. Notably, therapies targeting events immediately after AMI are restricted by a brief window of opportunity after initial myocardial damage or restoration of blood flow, and treatment needs to be timed accurately.

### 3.2.2 Leucocyte infiltration

Another approach to prevent excessive inflammation and associated tissue destruction post-MI is to prevent immune cells from infiltrating the damaged tissue (Table 3). Acute damage causes local inflammation, activation of endothelial cells in the vasculature and up-regulation of adhesion molecules such as integrins to recruit leucocytes. Neutrophils are among the first leucocytes to migrate into the myocardium. They clear cellular debris, promote macrophage infiltration, and are essential for cardiac repair and survival. Canine studies showed that neutrophil depletion reduces infarct size, however, post-MI neutropenia could delay cardiac repair and preventing their infiltration is associated with decreased survival in mice.

**Integrins.** Infiltration of leucocytes into damaged or inflamed tissues is mediated by adhesion molecules on activated endothelial cells. Up-regulation of cardiac αvβ3 integrin at recently infarcted sites (measured 2 weeks after AMI) predicts improved repair and recovery in human patients, and blocking P-selectin and intercellular adhesion molecule-1 (ICAM-1) in murine studies is beneficial post-MI. This supported the notion that inhibition of leucocyte infiltration might improve post-MI outcomes.

Although treatment with monoclonal antibodies against the integrin complex CD11/CD18 has reduced infarct size in pre-clinical studies, the corresponding clinical investigations in AMI patients have not been encouraging. The LIMIT-AMI study (2001) targeted CD18 in a study of 394 patients, but did not find any difference in coronary blood flow, infarct size, or the rate of ECG ST-segment elevation resolution. Similarly, the FESTIVAL study (2001) tested a monoclonal antibody against CD11/CD18 in 60 patients following coronary angioplasty and did not find any difference in infarct size at 30 day follow-up. There was also no improvement in infarct size measured 5–9 days following an anti-CD11/CD18 receptor antibody at either high or low dose in a 420 participant study in the HALT-MI (2002) investigation. These studies all measured infarct size or flow rate as primary outcomes. A trial measuring effects of anti-CD11/CD18 treatment on heart function would be informative.

**Mast cells.** The number of cardiac mast cells increases dramatically following MI, along with macrophages, and they influence the inflammatory process via histamine, growth factor, and cytokine release. They also induce fibroblast differentiation and modulate myocardial tissue healing and formation of the infarct scar.

Tranilast is an anti-fibrotic drug which prevents collagen synthesis by inhibiting the release of mast cell factors, including histamine, and prostaglandins. Two early trials (TREAT and TREAT 2) showed that 600 mg tranilast daily for 3 months caused a significant reduction in restenosis required for non-stented patients. On angiography, the TREAT trial (1999) reported a restenosis rate of 14.7% compared with 46.5% in the placebo group, and 18.8% compared with 44.1% in the TREAT-2 trial (2002). However, the PRESTO trial (2002) failed to show any improvement in quantitative measures of restenosis as measured by angiography and intravascular ultrasound in 11 484 patients treated with tranilast twice daily for 1 or 3 months, 4 h following PCI. There was no difference to placebo treatment in mortality, MI, or ischaemia-driven target vessel re-vascularization in the 9 month follow-up.

Histamine released by cardiac mast cells acts on two distinct histamine receptors type 1 and 2 (H1R and H2R), which increase endothelial permeability and exacerbate ischaemia/reperfusion injury I/R, resulting in increased infarct size. A single blind—blind trial by Mujtaba et al. with 60 STEMI patients prescribed 40 mg daily H2R antagonist famotidine upon hospital admission showed reduced LV dilation. However, LVEF was also decreased on echocardiography when followed up at day 30. Another trial by Kim et al. on 318 CHF patients, who received 30 mg famotidine daily for 6 months, showed reduced ventricular remodelling with a reduction in LV end-dia-stolic and end-systolic diameters, lower brain natriuretic peptide (BNP), and decreased NYHA functional class. Conversely however, a small study on 12 patients by Lucas et al. using three H2R antagonists (H2RA) cetirizine, famotidine and ranitidine administered for 7 days did not improve metabolic or exercise performance or LVEF upon echocardiography compared with placebo in NYHA Class II/III patients.

Thus far, clinical trials using early leucocyte accumulation as therapeutic target have included non-specific blocking of leucocyte migration by inhibiting the integrin complex CD11/CD18 and blocking of mast cell effector functions (Table 3). While the first approach has not yielded any beneficial effects, targeting mast cells seems a promising avenue worth exploring further. Importantly, as for ROS and complement targeting strategies, treatments need to be administered at the best time to suppress excessive infiltration, while maintaining healing responses and beneficial cardiac remodelling. This likely means a delay of immunomodulatory treatment of 2–3 days to maintain acute neutrophil and monocyte infiltration to support the initiation of the healing process, while blocking persistent infiltration and excessive accumulation within the tissue once the acute response should be cleared.

### 3.2.3 Adaptive immunity

MI not only triggers acute early inflammation, but also a substantial adaptive immune response against cardiac self-proteins. Due to the immunological memory of adaptive immune cells, this auto-reactivity in form of self-reactive T and B lymphocytes and auto-antibodies lingers, and has
| Study                         | Study population | Intervention | Dose/administration     | Follow-up | Outcome measures                      |
|------------------------------|------------------|--------------|-------------------------|-----------|---------------------------------------|
| **CD11/CD18 integrin inhibitors** |                  |              |                         |           |                                       |
| Faxon et al. (HALT-MI)        | 420              | STEMI        | Hu23F2G (Leukoarrest)   | 0.3 mg/kg OR 1 mg/kg IV bolus | 1 month   | Mortality (0); Infarct size (0); MACE (0). |
| Rusnak et al. (FESTIVAL)      | 60               | Anterior or inferior STEM (AMI) | Hu23F2G (Leukoarrest) | 0.3 mg/kg OR 1 mg/kg IV bolus | 6 weeks   | Infarct size (0); MACE (0); physical exam (0); Vital signs (0) |
| Baran et al. (LIMIT AMI)      | 394              | STEM (AMI)   | rhuMAb CD18             | 0.5 mg/kg OR 2 mg/kg IV bolus | 3 months  | Mortality (0); coronary blood flow (0); ECG STEMI resolution (0); infarct size (0); MACE (0); TIMI (0); CK-MB (0). |
| **Mast cells**                |                  |              |                         |           |                                       |
| Holmes et al. (PRESTO)        | 11484            | PCI (40%)    | Tranilast               | 300 mg OR 450 mg twice daily oral for 1 month OR 3 months | 9 months  | Mortality (0); MACE (0); MI (0), target vessel revascularization (0). |
| Tamai et al. (TREAT 2)        | 288              | Angina with previous MI (52.1%) with successful PTCA and de novo or restenotic coronary lesions | Tranilast | 600 mg daily oral for 3/12 | 12 months | MACE (0); restenosis (+); SAE (-). Target vessel revascularization (0). |
| Tamai et al. (TREAT)          | 247              | Angina with previous MI (39.7%) with successful PTCA and de novo lesions | Tranilast | 600 mg OR 300 mg daily oral for 3/12 | 12 months | MACE (0); restenosis (+); side effects (0); target vessel revascularization (0). |
| **Mujtaba et al.**            |                  |              |                         |           |                                       |
| Kim et al. (OLProspective)    | 50               | STEMI        | H2RA (famotidine)       | 40 mg daily | 1 month   | LVEF (+); LV dilation (+); NT-pro-BNP (+); BNP (0); fractional shortening (0); LV diameter (0); LVDd (0); LVDs (0); LVEDV (+); LVEDV (-); MACE (+). |
| **Lucas et al.**              |                  |              |                         |           |                                       |
|                               | 12               | CHF (NYHA II and III) (50%) | H2RA (famotidine, ranitidine) | 400 mg twice daily cimetidine and 40 mg famotidine daily and 150 mg daily ranitidine for 7 days each with a 7 day washout between each intervention | 7 days    | aerobic metabolic performance (0); exercise capacity (0); LVEF (0). |

BNP, B-natriuretic peptide; BU, blinding unknown; CHF, chronic heart failure; D, dexamethasone; DB, double blind; H2RA, histamine-2 receptor antagonist; IV, intravenous; LVDd, left ventricle dimensions in diastole; LVDs, left ventricle dimensions in systole; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVEDV, left ventricular end-systolic volume; MAb, monoclonal antibody; MACE, major adverse cardiac event; NYHA, New York Heart Association; OL, open label; PC, placebo controlled; PCI, percutaneous coronary intervention; PTCA, percutaneous transluminal coronary angioplasty; R, randomized; SAE, serious adverse events; STEMI, ST-elevation myocardial infarction; TIMI, thrombolysis in myocardial infarction; (0), supports intervention use; (-), supports placebo use; (0), no difference between intervention and placebo.
been suggested to cause ongoing tissue destruction, exacerbating the risk of developing HF.

**T lymphocytes.** Pre-clinical studies have shown that T lymphocytes accumulate in the infarct zone within minutes following I/R and that CD4+ T lymphocytes contribute to additional tissue injury.70

As discussed above, CsA was used as experimental post-MI treatment due to its role in blocking mPTP opening, and was therefore, expected to reduce mitochondrial dysfunction and cardiomyocyte death immediately after AML. However, CsA also targets calcineurin to inhibit the transcription of IL-2, IL-4, and CD40, cytokines and co-receptors important for effector T lymphocyte recruitment and function.71 Trials performed so far did not find any difference in cardiac damage as measured by cTnT levels, LVEF, infarct size, or all-cause mortality three days after infarct.25–27 These studies focused on the effects of CsA administration immediately after infarct. However, the adaptive immune system remains active long-term after MI. Therefore, considering that all-cause mortality did not change and CsA treatment was deemed safe, longer treatments and in particular longer follow-up periods may be worthwhile to investigate any long-term effect on cardiac remodelling and function.

The pro-inflammatory activity of effector T lymphocytes and other inflammatory immune cells is counterbalanced by the regulatory arm of the immune system, most prominently by T regulatory (Treg) cells. Experimental studies indicate an important role of Treg cells in improving post-MI tissue regeneration by modulating the function of other leukocytes.72 Treg cells have anti-inflammatory properties which promote skeletal muscle regeneration, and might therefore, also establish a pro-regenerative environment in the heart. Boosting the Treg cell population has been proven beneficial in a variety of inflammatory settings and might be a therapeutic avenue worth exploring in post-MI patients.73 Adenosine, a naturally occurring nucleoside increases Treg cell numbers,74 and although the rationale for its use post-MI was to protect cardiomyocytes from acute I/R, it has also been shown to reduce infarct size in pre-clinical studies by suppressing CD4+ effector T lymphocyte subsets.75 A meta-analysis of 15 randomized-controlled trials involving 1736 patients with AMI undergoing PCI reported a reduction in HF development with adenosine use, but there was no overall improvement in LVEF or survival.75 Confirmation of any effects on the adaptive immune system would be informative. No clinical trials specifically targeting the Treg cell population have been performed yet.

**B lymphocytes.** DAMPs and damaged myocardial tissue activate circulating CD20+ B lymphocytes. These selectively produce the chemokine CCL7, which causes inflammatory monocytes to migrate from the bone marrow into the circulation. High circulating levels of CCL7 and B cell activating factor (BAFF) were associated with higher rate of mortality in patients with recurrent MI. Antibody-mediated depletion of CD20 or BAFF in experimental MI models reduced inflammatory recruitment and improved cardiac function.76 Rituximab is an anti-CD20 antibody used clinically to treat inflammatory autoimmune diseases and B lymphocyte cancers. The RITA-MI study is currently recruiting participants to test its clinical efficacy and safety in AMI.77

### 3.2.4 Inflammatory cytokines

A long list of cytokines and chemokines has been implicated in post-MI inflammation, but the best studied cytokine targets post-MI to date are IL-1, IL-6, and TNF. Study characteristics for clinical trials on cytokine inhibition are shown in Table 4.

**Interleukin-6.** IL-6 may have both pro- and anti-inflammatory properties and can activate the PI3K pathway, which is associated with adaptive hypertrophy and protects cardiomyocytes from apoptosis.94,95 IL-6 levels post-MI correlate with increased CRP production, which is a predictor of progression and future risk of coronary heart disease.96

Tocilizumab is an IL-6 receptor antagonist used as anti-inflammatory therapy for rheumatoid arthritis.97 A recent study by Kleveland et al.85 in 117 non-ST elevation MI (NSTEMI) patients undergoing coronary angiography showed significantly lower levels of high-sensitivity CRP (hs-CRP) and cTnT after tocilizumab administration over 3 days hospitalization. This was particularly substantial in acutely treated patients and during percutaneous PCI, which suggests cardio-protective potential during I/R. A subsequent study by Holte et al.84 found no difference in coronary flow reserve (CFR), as a reflection of endothelial function, in these patients over 6 months follow-up, suggesting tocilizumab influences systemic inflammation as measured by CRP, not coronary endothelial function. The recent STAT-MI trial ended early as futility analysis showed low likelihood of reaching the primary outcome, with authors attributing early termination to insufficient subject recruitment. The results for 28 patients showed no significant change in MACE, CRP, or ECG.86,98

**Interleukin-1.** IL-1α is a cytokine released from necrotic cardiomyocytes and acts as a danger signal triggering acute inflammation and healing following MI.99 IL-1β is released by activated leukocytes within hours post-MI and has been implicated in leukocyte infiltration and ventricular remodelling.100,101 Importantly, pre-clinical data showed that antibody-mediated IL-1β neutralization reduced post-MI inflammation, adverse remodelling, and HF in mice.102,103

Anakinra is a recombinant competitive non-specific IL-1 receptor antagonist (IL-1RA) and has been used for the treatment of rheumatoid arthritis.104 Clinical trials using anakinra have shown significant down-regulation of systemic inflammation as measured by CRP in acute compensated HF,79 NSTEMI ACS90 and AMI.82 Sonnino et al.82 also reported decreased IL-6 levels 3 months after anakinra treatment in AMI. In a small pilot study, Abbate et al.82 randomized 10 patients to either anakinra or placebo. Over a 10–14 week follow up period, improvements in LV remodelling with a drop in LV end-systolic volume index (LVESVI) were measured by CMRI. However, large and adequately powered studies are required to assess the safety and efficacy of anakinra, as Van Tassell et al.79 did not show a reduction in MACE up to two weeks after treatment with anakinra in 30 HF patients and another study (Morton et al.80) showed increased markers of inflammation and re-infarct rates following discontinuation of anakinra.

Canakinumab is a monoclonal antibody that specifically neutralizes the pro-inflammatory effects of IL-1β.105 Ridker et al.83 tested canakinumab treatment in 556 type-2 diabetes patients at high risk of MI and found an improvement in overall inflammatory measures. Recently the CANTOS trial (2017) studied the effect of canakinumab in 10 061 patients with previous MI and raised CRP levels. Canakinumab significantly reduced CRP levels compared with placebo, and it also significantly lowered the incidence of recurrent non-fatal MI, non-fatal stroke, and cardiovascular-related death after 2 years follow-up.78

The above studies were analysed for their risk of bias profiles (Figure 3A). In two studies, we identified ‘other bias’, which is defined as ‘sources of bias relevant only in certain circumstances or not covered by the other headings’. Sonnino et al. (2014) was classified as such because studies were performed on ex vivo peripheral blood leucocytes.81

---

**Table 4.** Characteristics for clinical trials on cytokine inhibition

| Cytokine | Study Population | Study Duration | Treatment | Control | Primary Endpoints | Secondary Endpoints |
|----------|-----------------|----------------|-----------|--------|------------------|--------------------|
| IL-6     |                |                | Tocilizumab| Placebo| Improved cardiac function | Reduced inflammation |
|          |                |                | Anakinra  | Placebo|                 |                    |
| IL-1α    |                |                | Canakinumab| Placebo|                 |                    |
| IL-1β    |                |                | Canakinumab| Placebo|                 |                    |

---

**Figure 3A.** Risk of bias profiles for clinical trials on cytokine inhibition.
### Table 4 Study characteristics of clinical trials using cytokine inhibition

| Study | Design | n | Study population | Intervention | Dose/administration | Follow-up | Outcome measures |
|-------|--------|---|------------------|--------------|---------------------|-----------|------------------|
| **IL-1 inhibitors** |
| Ridker et al.⁷⁸ (CANTOS) | R, DB, PC | 10 061 | Previous MI | Canakinumab | 150 OR 200 OR 300 mg | 3.7 years | Mortality (0); MACE (+); SAE (-); CRP (+); LDL (-). |
| Van Tassell et al.⁷⁹ | R, DB, PC | 30 | HF (33.3%) | Anakinra | 100 mg twice daily for 3 days + daily for 11 days | 2 weeks | MACE (0); clinical cardiac exam (0); LVEF (+); CRP (+); IL-6 (+); IL-17 (0); p-PLA2 (0); Leptin (0); MPO (+); NT-pro-BNP (0); galectin 3 (0); TNFa (0); hs-TnI (+). |
| Morton et al.⁸⁰ (MRC-ILA Heart Study) | R, DB, PC | 182 | ACS (26%) | Anakinra | 100 mg sc once only | 1 year | Mortality (0); MACE (-); hs-CRP (+); FBC (0); IL-6 (+); platelets (+); TnT (0); TnI (0); WCC (+). |
| Sonnino et al. | R, DB, PC | 17 | AMI | Anakinra | 100 mg | 3 months | IL-6 (+). |
| Abbate et al.⁸² (VCU-ART) | R, DB, PC | 10 | AMI | Anakinra | 100 mg sc daily for 2 weeks | 3.5 months | CRP (+); fibrinogen (+); HbA1c (0); IL-6 (+). |
| Ridker et al.⁸³ | R, DB, PC | 556 | T2DM with high-MI risk | Canakinumab | 5 OR 15 OR 50 OR 150 mg | 4 months | CRP (+); fibrinogen (+); HbA1c (0); IL-6 (+); triglyceride (-). |
| **IL-6 inhibitors** |
| Holte et al.⁸⁹ | R, DB, PC | 117 | NSTEMI | Tocilizumab | 280 mg IV | 6 months | Coronary flow reserve (0); VCAM-1 (+) |
| Kleveland et al.⁹⁰ | R, DB, PC | 117 | NSTEMI | Tocilizumab | 280 mg IV | 6 months | LVEF (0); SAE (0); nt-proBNP (0); Hb (0); hs-CRP (+); leukocytes (+); lipids (0); platelets (0); hs-TnT (+). |
| Carroll et al.⁹¹ | R, DB, PC | 28 | MI | Tocilizumab | 162 mg sc | 1 month | MACE (0); CRP (0); ECG (0). |
| **TNF inhibitors** |
| Padfield et al.⁹⁷ | R, DB, PC | 26 | MI | Etanercept | 10 mg IV | 24 h | IL-6 (+); neutrophil (+); platelet-monocyte aggregate (+); t-PA (0). |
| Mann et al.⁹⁷ (RENAISSANCE) | R, DB, PC | 1123 | CHF (16.3%) | Etanercept | 25 mg sc BW OR TIW | 24 weeks | Mortality (0); MACE (0). |
| Mann et al.⁹⁸ (RECOVER) | R, DB, PC | 925 | CHF (20%) | Etanercept | 25 mg sc QW OR BIW | 5.5 months | Mortality (0); MACE (0); Clinical composite score (0); LVEF (0); CRP (+); IL-6 (+); worsened heart failure (+); mortality (+) |
| Chung et al.⁹⁹ (ATTACH) | R, DB, PC | 150 | CHF | Infliximab | 5 or 10 mg/kg | 28 weeks | Adverse events; functional status (O); LVEF (+); LVESV (+); LVEDV (+); LV mass (O). |
| Bozkurt et al.¹⁰¹ | R, DB, PC | 47 | HF (82%) | Etanercept | 5 mg/m² OR 12 mg/m² sc BW for 3 months | 3 months | Endothelium dependent forearm blood flow (+); endothelium independent flow (0) |
| Fichtlscherer et al.¹⁰² | ND, OL, NPC | 18 | HF (50%) | Etanercept | 25 mg sc QW | 7 days | EF (+); 6MWT (+); QOL scores (+). |

ACS, acute coronary syndrome; T2DM, Type 2 diabetes mellitus; NSTEMI, non-ST elevation myocardial infarction; sc, subcutaneous injection; BW, twice weekly; TIW, three times a week; QW, once weekly; p-PLA2, lipoprotein-associated phospholipase A2; MPO, myeloperoxidase; Nt-proBNP, N-terminal pro B-type natriuretic peptide; TnT, troponin T; FBC, full blood count; WCC, white cell count; LVESV, left ventricular end-systolic volume index; HbA1c, haemoglobin A1c; VCAM-1, vascular cell adhesion protein 1; Hb, haemoglobin; SAE, serious adverse events; t-PA, tissue plasminogen activator; EF, ejection fraction; R, randomized; DB, double blind; PC, placebo controlled; MACE, major adverse cardiac event; hs-CRP, high-sensitivity C-reactive protein; LVEF, left ventricular ejection fraction; TNF, tumour necrosis factor; ECG, electrocardiogram; (+), supports intervention use; (-), supports placebo use; (0), no difference between intervention and placebo; 6MWT, 6 min walk test; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume.
Abbate et al. (2010) was excluded, because it was a small pilot study with only 10 patients with a greater risk of strong impact by outliers. 83 Both studies, as well as Ridker et al. (2012) did not measure MACE, so were excluded from meta-analysis. 83 The three remaining trials measured MACE and were included in meta-analysis. 78–80 Of 10 273 patients, 30 were classified as HF and 10 243 as high risk of HF. The risk ratio (RR) and confidence intervals (CIs) for mortality and MACE were calculated as 1.07 (0.52–2.22) showing that overall mortality and MACE in the treated groups was not decreased compared to the placebo groups (Figure 3B). However, these studies still present a significant heterogeneity in study design and population (secondary prevention in patients at high risk of MI, HF, or ACS patients) and tested drug (canakinumab or anakinra).

The CANTOS study was still a major step forward investigating a more targeted approach to immunomodulation following MI. It was however, primarily focused on preventing atherosclerosis and results are assumed to be due to a reduction of systemic inflammation, and subsequently less thrombosis-mediated cardiovascular events. Measurements of cardiac functional or morphological parameters would have allowed a conclusion about direct effects on the heart.

TNF. TNF promotes leucocyte infiltration by up-regulating transcription of adhesion molecules and chemokines. However, TNF also demonstrates pleiotropic effects in delaying myocardocyte apoptosis following acute ischaemia. 106 Etanercept is a high affinity TNF receptor which has been licensed for treatment of rheumatoid arthritis. 107 A small early study of etanercept by Deswal et al. 83 given to 12 HF patients appeared to improve ejection fraction and 6MWT performance over placebo control subjects. In another study by Fichtlscherer et al. 92 etanercept treatment of 13 CHF patients seemed to increase endothelium-dependent forearm blood flow as compared with 5 control patients, but not endothelium-independent, suggesting improvement in systemic endothelial vasoreactivity. Bozkurt et al. 91 performed a trial using biweekly subcutaneous injections of etanercept 5 mg/m² (n = 16) or 12 mg/m² (n = 15) or with placebo (n = 16) for 3 months in patients with NYHA Class III to IV HF and showed dose-dependent improvement in LV structure and function, with improved NYHA class when compared to placebo.

During the RECOVER and RENNAISANCE studies, NYHA Class III to IV CHF patients received placebo (n = 373) or 25 mg of etanercept once, twice, or three times per week (n = 375 each group). No clinical or survival improvements were observed after nearly 2 years, and therefore, both studies were prematurely terminated. 88 Joint analysis (RENEWAL) of both trials rules out a clinically relevant benefit of etanercept on the rate of death or hospitalization due to CHF. 89

A final trial using etanercept by Padfield et al. 87 in a 26 patient AMI study also failed to show beneficial clinical effects and found that in fact reductions in neutrophil and IL-6 levels correlated with increased platelet and monocyte activation.

Another TNF inhibitor, the chimeric monoclonal antibody infliximab, was used at 5 or 10 mg/kg at 0, 2, and 6 weeks in a trial on 150 patients with moderate-to-severe HF, but no improvement in clinical status was observed despite suppression of inflammatory markers CRP and IL-6. However, there was a higher ratio in adverse effects noted in the 10 mg/kg infliximab group. 90

The original rationale behind targeting inflammatory cytokines as preventive strategy as well as post-MI stems largely from the emerging concept of atherosclerosis as an inflammatory disease. Preventing an exacerbation of atherosclerosis by targeted anti-inflammatory treatments, previously shown to be effective in systemic autoimmune disease, was anticipated to protect from recurrent cardiovascular events. Importantly however, besides decreasing systemic inflammation, studies on IL-1 receptor antagonist anakinra suggest the potential for effects on heart tissue function and remodelling. 82 This allows a first promising glimpse into the potential benefit of these therapies in protecting from adverse remodelling and development of HF post-MI.

4. Considerations for future research and trial design

An enormous amount of effort and resources has gone into a wide range of immunomodulatory trials (Figure 1), which have accumulated a wealth of invaluable information to allow future trials to be designed in the most efficient way. Yet to date, practical challenges dealing with a highly diverse post-MI patient population, and striking heterogeneity in trial design means evidence available in support of immunomodulatory...
treatment is still inconclusive. We recommend consideration of the following factors to achieve standardization in the design of future clinical trials.

### 4.1 Therapeutic strategy and target

Due to the dynamic nature of the post-MI immune response, small variations in exact target, timing, and dosage can lead to tremendous differences in the effect on the immune response. In addition, both pre-MI and early post-MI clinical situation affect long-term complications, including the development towards HF. Early and late phase post-MI should therefore not be looked at in isolation. When interpreting the currently available information on immunomodulation trials, it is crucial to discriminate between studies on pre-MI prevention, AMI recovery, or CHF mortality. Most trials so far have focused on AMI, thus investigated early effects only. Future trials need to carefully consider the best time point for drug administration to optimize acute infarct healing and long-term functional recovery.

### 4.2 Routine medication/therapy

Currently used routine post-infarct medication affect the immune response, and this may have significant impact on experimental treatments and may result in unexpected outcomes if routine treatment is changed. There are several prominent examples of routine medication with either pro- or anti-inflammatory effects. Platelet inhibitors such as aspirin and clopidogrel attenuate platelet-leucocyte interaction, thus suppress ROS formation, leucocyte activation, and expression of pro-inflammatory cytokines. Statins, which are still used to block the production of low-density lipoprotein (LDL) cholesterol, down-regulate effector T lymphocytes, while increasing expression of Treg cell markers, IL-10, and low-density lipoprotein (LDL) cholesterol, down-regulate effector T cells.

### 4.3 Patient population

Trial results also hint towards the need of a stratified approach to immunomodulatory care of post-MI patients, as some patient groups may respond and benefit significantly more than others. The post-MI population is strikingly heterogeneous and the risk of poor outcome and development to HF is influenced by several factors including demographics, genetics and pre-existing immunological, and metabolic conditions. It seems feasible that immunomodulatory treatment may be most beneficial for patients with a raised inflammatory profile and the CANTOS trial has indeed provided first evidence for this hypothesis.

### 4.4 Combination therapy

While the immune response is certainly a crucial player in post-MI wound closure and restoration of tissue integrity, its modulation will likely only prevent ongoing damage rather than replacing tissue already lost. Long-term benefits on heart function are more likely to be achieved if immunomodulation is combined with regenerative therapies such as biomaterial-based strategies or cell therapies aiming to replace damaged cardiomyocytes. Combination therapy will not only prevent ongoing damage, but also provide therapies with a local environment permissive of regeneration. Numerous studies have been undertaken in recent years to evaluate the effect of stem cell mobilization, recruitment or transplantation into the myocardium. One approach particularly interesting in this context is the use of mesenchymal stem/stromal cells (MSC). MSC themselves combine cell therapy with immunomodulation due to their stem cell-like and immunosuppressive characteristics. Although it has become clear that their initially assumed immunoprivilege may be lost upon differentiation, a Phase III randomized comparison (POSEIDON study) of trans-endocardial injection of MSCs in patients with LV dysfunction showed positive effects on functional capacity, quality of life, and ventricular remodelling. Once both immunomodulatory strategies and cardiac regenerative cell therapy have overcome current hurdles, the combination might be able to achieve astonishing results.

### 4.5 Complications of immunotherapies

Cost-benefit ratios and incidence of severe side effects need to be carefully considered and investigated before administration of post-MI immunotherapies. A tightly regulated balance between immune activation and regulation ensures efficient responses against infections and cancers, while preventing autoimmunity. Suppressing all or part of the immune system post-MI may impact on wound healing and regenerative processes in other areas of the body, weaken defences against infectious diseases, and undermine the ability of the immune system to detect and destroy malignant growth early on. Chronic immunosuppressive treatment using methotrexate, cyclosporine, or anti-TNF reagents is known to carry an increased risk of lymphoma, due to decreased immunosurveillance. Importantly however, these potentially serious complications need to be assessed for individual treatments and will depend on the specific role of the immunomodulation target in the relevant settings. For example, IL-1β inhibition with canakinumab during the CANTOS trial reduced the incidence of lung cancer and lung cancer mortality, while fatal infections and sepsis were more common in the canakinumab treated group.

### 5. Recommendations for standardization of future post-MI immunomodulatory trials

#### 5.1 Start of treatment

To ensure the initiation of an appropriate wound healing response, administration of strong immunosuppressive treatment within 24h after AMI should be avoided. Two to 3 days post-MI may be a more beneficial time point causing less adverse effects. This may be hard to achieve with strategies targeting events or factors immediately post-MI (e.g. ROS, complement). Notably, due to its effects on the adaptive immune system, CsA which has been used safely (albeit without clinical effects) at early time points, with the aim to prevent immediate post-MI cardiomyocyte death, may be a worthwhile candidate to explore for its long-term effects on HF development. Trials targeting mast cells have also yielded promising results and they may benefit from a wider therapeutic window, allowing treatment to be delayed for a few days post-MI.

So far, the maybe greatest patient benefit of immunomodulatory treatment was achieved by IL-1 inhibition (CANTOS trial) in previous MI patients with raised inflammatory profiles, thus at greater risk of developing subsequent MIs or HF. Due to the delay post-MI, this patient population was likely beyond the acute phase of wound healing and inhibition of a potent inflammatory mediator successfully decreased systemic inflammation without affecting early healing.
5.2 Outcome measures
Besides MACE, outcome measures to allow an assessment of both acute and long-term benefits of immunomodulatory treatment should include functional and morphological measurements such as LV ejection fraction and diameters as assessed by echocardiography or MRI. Importantly, these should be obtained at baseline and at defined time points following AMI (e.g. 1 month, 3 months, 1 year, 2 year, and 4 year following MI). Considering that 63% of MI patients develop HF within 6 years post-MI, shorter follow up periods will not allow to judge if the treatment affects development towards HF. Incorporating measurement of CRP and BNP or NT-pro BNP will help identify patients’ response to therapies and identify patients at risk of overt immune suppression. Measuring adaptive immune auto-reactivity against the heart (e.g. serum auto-antibody levels) would further improve our understanding of the immunological factors involved in post-MI HF development.

Acknowledgements
The authors are grateful to Dr Vivek Philip and Dr Krishna Karuturi at Computational Sciences, The Jackson Laboratory, Bar Harbor, USA, for advice on statistical models and analysis and to Ms Sarah Wong, Imperial College London, UK, for critical reading of the manuscript.

Conflict of interest: none declared.

Funding
This work was supported by the British Heart Foundation [PG/16/93/32345] and by the Leuqoc Foundation Transatlantic Network of Excellence in Cardiac Research: Cellular and molecular targets to promote cardiac regeneration.

References
1. Wang H, Naghavi M, Allen C, Barber RM, Bhutta ZA, Carter A, Casey DC, Charlson F, Choa J, Coates MM, Coggeshall M, Dandona L, Dicker DJ, Erskine HE, Ferrari AJ, Fitzmaurice C, Foreman K, Forouzanfar MH, Fraser MS, Fullman N, Gething PW, Goldberg GM, Graetz N, Haagsma JA, Hay SI, Huying C, Johnson CO, Kassebaum NJ, Khang Y-H, Lozano R, Mensah GA, Morbidity and Mortality Weekly Report
2. Torabi A, Cleland JGF, Khan NK, Loh PH, Macario A, Malhotra A, Morgan D, Novak I, Oudemans-van 3. Frangogiannis NG. Regulation of the inflammatory response in cardiac repair. Circ Res 2012;110:159–173.
4. Meher D, Liberati A, Teitelj J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.
5. Coenen AL, Oxman AD, Vist GE, Kunz R, Flicek-Yetter Y, Alonso-Coello P, Schünemann HJ. GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924–926.
6. Sattler S, Panahi M, Papanikolaou A. PROSPERO International Prospective Register of Systematic Reviews: Comparison of Immune-Suppressive and Immune-Modulatory Interventions following Acute Myocardial Infarction and during Heart Failure: A Systematic Review. 18th January 2018. CRD42017079918.
7. MedCalc Software. MedCalc Statistical Software. https://www.medcalc.org/index.php (28 June 2018, date last accessed).
8. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–188.
9. Lopes CR, Jr, Jun P. Systematic reviews and meta-analyses of randomized trials: principles and pitfalls. Eur Heart J 2014;35:3336–3345.
10. Christa P, Frangogiannis NG. Targeting inflammatory pathways in myocardial infarction. Eur J Clin Invest 2013;43:986–995.
11. Giugliano GR, Giugliano RP, Gibson CM, Kuntz RE. Meta-analysis of corticosteroid treatment in acute myocardial infarction. Am J Cardiol 2003;91:1055–1059.
12. Damiano RJ, Anderegg LW, Berg KM, Chase M, Sherwin R, Smithline H, Carney E, Ng N, Patel PV, Liu X, Cutlip D, ZiemBaum P, Cocchi MM. Corticosteroid therapeutically in refractory shock following cardiac arrest: a randomized, double-blind, placebo-controlled trial. Crit Care 2016;20:82.
13. Liu C, Liu K. Cardiac outcome prevention effectiveness of glucocorticoids in acute decompensated heart failure. J Cardiovasc Pharmacol 2014;63:333–338.
14. Mentzelopoulos SD, Malachas S, Chamos C, Konstantopoulos D, Ntatsou T, Kyprianou G, Kolaris G, Coppola M, Theodoridis M, Iossif D, Makris D, Zakyntinos E, Zintzaras E, Soulias S, Aloizos S, Zakyntinos SG. Vasopressin, steroids, and epi-nephrine and neurologically favorable survival after in-hospital cardiac arrest. JAMA 2013;310:270.
15. Tsai MS-H, Huang C-H, Chang W-J, Chen Y-C, Hsieh C-C, Yang J-C, Wang W-C, Hsueh-Ming Ma M, Chen S-C. The effect of hydrocortisone on the outcome of out-of-hospital cardiac arrest patients: a pilot study. Am J Emerg Med 2007;25:318–325.
16. Moreira DM, Luebbenmeier ME, da Silva RL, Fattah T, Gottschall CA. Methotrexate T Therapy in ST-Segment Elevation Myocardial Infarction: a randomized double-blind, placebo-controlled trial (TETHTYIS Trial). J Cardiovasc Pharmacol Ther 2017; doi: 10.1177/1074916617699888.
17. Everett BM, Pradhan AD, Solomon DH, Paynter N, Macfadyen J, Zaharias E, Gupta M, Clearfield M, Libby P, Hasan AAK, Blum J, Ridker PM. Randomized and therapeutic value of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J 2013;166:199.
18. Moreira DM, Viera JL, Mascia Gottschall CA. The effects of methotrexate therapy on the metabolic capacity of patients with ischemic heart failure: a randomized double-blind, placebo-controlled trial (METIS Trial). J Card Fail 2009;15:828–834.
19. Feng G, Zhang Z, Sun X, Zhang X, Li A, Yan J, Luo Q, Gao Y, Feng T. The non-specific anti-inflammatory therapy with methotrexate for patients with chronic heart failure. Am Heart J 2006;151:62–68.
20. Hauserley D, Kunst G, Boston-Griffiths E, Kolverc S, Chaubey S, John L, Desai J, Yenchen D. The effect of methotrexate on peri-operative myocardial injury in adult patients undergoing coronary artery bypass graft surgery: a randomised controlled clinical trial. Heart 2014;100:544–549.
21. Chiarl P, Angoulvant D, Mewton N, Desebbe O, Odina J, Robin J, Farhat F, Jegden O, Bastien P, Lehto J, Oviye M. Cyclosporine protects the heart during aortic valve surgery. Anesthesiology 2014:121:232–238.
22. Yinghong C, Lin C, Chunbin W. Clinical effects of cyclosporine A on reperfusion injury in myocardial infarction: a meta-analysis of randomized controlled trials. Springerplus 2015;4:1117.
23. Gullestad L, Rom S, Dickstein K, Eek C, Edvardsen T, Aaksu S, Askevold MT, Michelsen A, Bendz B, Skårdal R, Smith HJ, Yndestad A, Ueland T, Aukrust P. Intravenous immunoglobulin does not reduce left ventricular remodeling in patients with chronic heart failure. Circulation 2010;121:212–218.
24. Gullestad L, Aas H, Hjelde JG, Wikeye L, Andreasen AK, Iihonen H, Simonsen S, Kjeskus J, Jørgen-Hauge S, Ueland T, Lien E, Freland SS, Aukrust P. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 2001;103:220–225.
25. Gopel-Strobe M, Wolter D, Resch K. Glucocorticoids inhibit prostaglandin synthesis not only at the level of phospholipase A2 but also at the level of cyclo-oxygenase/PGE isomerase. Br J Pharmacol 1991;105:1055–1059.
26. Tian H, Cronstein BN. Understanding the mechanisms of action of methotrexate: evidence not only at the level of phospholipase A2 but also at the level of cyclo-oxygenase/PGE isomerase. Br J Pharmacol 1991;105:1055–1059.
27. Yingzhong C, Lin C, Chunbin W. Clinical effects of cyclosporine A on reperfusion injury in myocardial infarction: a meta-analysis of randomized controlled trials. Springerplus 2016;5:1117.
28. Gullestad L, Rom S, Dickstein K, Eek C, Edvardsen T, Aaksu S, Askevold MT, Michelsen A, Bendz B, Skårdal R, Smith HJ, Yndestad A, Ueland T, Aukrust P. Intravenous immunoglobulin does not reduce left ventricular remodeling in patients with chronic heart failure. Circulation 2010;121:212–218.
29. Gopel-Strobe M, Wolter D, Resch K. Glucocorticoids inhibit prosta glandin synthesis not only at the level of phospholipase A2 but also at the level of cyclo-oxygenase/PGE isomerase. Br J Pharmacol 1991;105:1287–1295.
30. Tian H, Cronstein BN. Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis 2007;66:168–173.
31. Naveed D, Haragni L. Cyclosporine: a review. J Transplant 2012;2:1–7.
32. Hennsen DJ, Boston-Griffiths E, Ydell LM. Cyclosporin A and cardioprotection: from investigative tool to therapeutic agent. Br J Pharmacol 2012;165:1235–1245.
33. Sewell WC, Jolles S. Immunomodulatory action of intravenous immunoglobulin. Immunology 2002;107:387–393.
33. Jolles J, Sewell WAC, Misch SA. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol 2009;154:1–11.

34. Kloner RA, Fahbel MC, Lew H, Maroko PR, Braunwald E. Mummification of the infarcted myocardium by high dose corticosteroids. Circulation 1978;57:56.

35. Roberts R, DeMello V, Sobel BE. Deleterious effects of methylprednisolone in patients with myocardial infarction. Circulation 1976;53:204–206.

36. Véranéau E, Ceretti C, Bianchi ME. DAMPs from cell death to new life. Front Immunol 2015;6:422.

37. Pasupathy S, Taubell R, Grover S, Raman B, Procter NE, Du Y, Mahadavan G, Stafford J, Herestyn T, Holmes DR, Savage M, LaBlanche J-M, Grip L, Serruys PW, Fitzgerald P, Fischman DJ. Early treatment with N-acetylcysteine (NAC) in acute coronary syndrome (ACOST) trial. Circulation 2012;126:894–903.

38. Yesilbursa D, Sertar T, Sener M, Akgun A, Aydogan A, Abravanel M, Senturk T, Serdar Z, Gonen N. Effect of oral H2- receptor antagonists on left ventricular systolic function and exercise capacity in patients with chronic stable heart failure. Pharmacotherapy 1998;18:824–830.

39. Ma Y, Yabulanychiev A, Lindsey ML. Neutrophil roles in left ventricular remodeling following myocardial infarction. FIBrous Tissue Repair 2013;6:11.

40. Rommel JL, Hook BG, Kunkel S, Abrams DJ, Goldberg S, Brinker JA, Zeiher AM, Shapiro LM, Willerson J, Davis BR, Ferguson JS, Saoud JB, Feldman RL, Breisblatt WM, Simons M, Gessler CJ, Yu AS. An anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for Limitation of Myocardial Infarction Following Thrombolysis in Acute Myocardial Infarction (LIMIT AMI) study. Circulation 2006;114:1028–1033.

41. Salmi-Aho S, Cuppari SR, Verdel-Caver A, Yamakawa K, Karvonen M, Slivka AM, Schroeder LJ, Hillmen DE. Effect of oral H2-receptor antagonists on left ventricular systolic function and exercise capacity in patients with chronic stable heart failure. Pharmacotherapy 1998;18:824–830.

42. Arstall MA, Yang J, Stafford I, Heresztyn T, Akhtar M, Selvanayagam J, Horowitz JD, Beltrame JF. Early use of N-acetylcysteine (NAC) with nitrate therapy in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction reduces myocardial infarct size (the NACIAM trial). Circulation 2012;126:894–903.

43. Fattouch K, Bianco G, Speziale G, Sampognaro R, Lavalle C, Guccione F, Dioguardi N, Lauri G, Zizza G, Smolenski RT, Yacoub MH, Suzuki K. A novel strategy for myocardial protection by combined antibody therapy inhibiting both P-selectin and intercellular adhesion molecule-1 via retrograde intraarterial route. Circulation 2006;114:1251–1256.

44. Franzen NGGS, Pierrard JL, Mendoza LH, Burns AR, Lindsey ML, Ballantyne CM, Michael LH, Smith CW, Entman ML. Stem cell factor induction is associated with mast cell accumulation after canine myocardial ischemia and reperfusion. Circulation 1998;98:678–689.

45. Chancey AL, Brower GL, Janicki JS. Cardiac mast cell-mediated activation of gelatine and alteration of ventricular diastolic function. Am J Physiol Heart Circ Physiol 2002;282:H152–H158.

46. Asahwa H, Kikuchi S, Arai N, Koda A. The mechanism involved in the inhibitory action of tranilast on collagen biosynthesis of keloid fibroblasts. Jpn J Pharmacol 1992;50:91–96.

47. Mackins CJ, Kano S, Seyedi N, Schäfer U, Reid AC, Machida T, Silver RB, Levi R. Cardiac mast cell-derived renin promotes local angiotensin formation, norepinephrine release, and arrhythmias in ischemia/reperfusion. J Clin Invest 2006;116:1033–1040.

48. Luo T, Chen B, Zhao Z, He N, Zeng Z, Wu B, Fukushima Y, Dai M, Huang Q, Xu D, Bin J, Kimataki M, Liao Y. Histamine H2 receptor activation exacerbates myocardial ischemia/reperfusion injury by disturbing mitochondrial and endothelial function. Basic Res Cardiol 2013;108:342.

49. Yang Z, Day YJ, Toufektsian M-C, Xu Y, Ramos JS, Marshall MA, French BA, Linden J. Myocardial infarction-sparing effect of A2A receptor activation is due to its action on CD4+ T lymphocytes. Circulation 2006;114:2064–2064.

50. Rao A, Luo C, Hogan PG. Transcription factors of the NFKT family: regulation and function. Annu Rev Immunol 1997;15:707–747.

51. Weirather J, Hofmann UDW, Beyersdorf N, Ramos GC, Vogel B, Frey A, Ertl G, Kerka T, Frantz S. Fontx3+ CD4+ T cells improve healing after myocardial infarction by modulating monocyte/macrophage differentiation. Circ Res 2014;115:55–67.

52. Burzyn D, Kuswoltoni K, Sladich JL, Cerletti M, Jang Y, Sekel F, Tan TG, Wagers AJ, Benoist C, Mathis D. A special population of regulatory T cells potentiates muscle repair. Cell 2013;155:1282–1295.

53. Ohta A, Sitkovsky M. Extracellular adenosine-mediated modulation of regulatory T cells. Front Immunol 2015;6:304.

54. Gupta Q, Yang B, Guo Y, Zheng F. Efficacy of adenosine in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: a PRISMA-compliant meta-analysis. Medicine 2015;94:e1279.

55. Zouggari Y, Ait-Oufella H, Bonnin P, Simon T, Sage AP, Guérin C, Vilar J, Caligiuri D, Kano S, Seyedi N, Schäfer U, Reid AC, Machida T, Silver RB, Levi R. Cardiac mast cell-derived renin promotes local angiotensin formation, norepinephrine release, and arrhythmias in ischemia/reperfusion. J Clin Invest 2006;116:1033–1040.

56. Ohta A, Sitkovsky M. Extracellular adenosine-mediated modulation of regulatory T cells. Front Immunol 2015;6:304.

57. Gupta Q, Yang B, Guo Y, Zheng F. Efficacy of adenosine in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: a PRISMA-compliant meta-analysis. Medicine 2015;94:e1279.

58. Zouggari Y, Ait-Oufella H, Bonnin P, Simon T, Sage AP, Guérin C, Vilar J, Caligiuri D, Kano S, Seyedi N, Schäfer U, Reid AC, Machida T, Silver RB, Levi R. Cardiac mast cell-derived renin promotes local angiotensin formation, norepinephrine release, and arrhythmias in ischemia/reperfusion. J Clin Invest 2006;116:1033–1040.

59. Ohta A, Sitkovsky M. Extracellular adenosine-mediated modulation of regulatory T cells. Front Immunol 2015;6:304.

60. Gupta Q, Yang B, Guo Y, Zheng F. Efficacy of adenosine in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: a PRISMA-compliant meta-analysis. Medicine 2015;94:e1279.
168. Short-Term Application of Tocilizumab Following Myocardial Infarction—Full Text View—ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/study/NCT02419937 (28 June 2018, date last accessed).

169. Lugrin J, Paraparorov R, Rosenblatt-Velin N, Rignaut-Clerc S, Seifl F, Waebber B, Müller O, Vergely C, Zeller M, Tardivel A, Schneider P, Pacher P, Laiudet C. Cutting edge: IL-1α is a crucial danger signal triggering acute myocardial inflammation during myocardial infarction. J Immunol 2015;194:499.

170. Qian S, Ueland T, Manenke C, Sandanger Ø, Mollnes TE, Dickstein K, Aukrust P. Increases interleukin-1β levels are associated with left ventricular hypertrophy and remodeling following acute ST segment elevation myocardial infarction treated by primary percutaneous coronary intervention. J Int Med 2012;272:267–276.

171. Saxena A, Chen W, Su Y, Rai V, Uche OU, Li N, Frangogiannis NG. IL-1 induces persistent myocyte lipid infiltration and regulates fibrinoblast phenotype in the infarcted myocardium. J Immunol 2013;191:4838–4848.

172. Sager HB, Heidt T, Hulsmans M, Dutta P, Courties G, Sebas M, Wijkspitzewicz GR, Tridici B, Iwamoto Y, Sun Y, Weisleeder R, Libby P, Swibski F, Nahrendorf M. Targeting interleukin-1β reduces leukocyte production after acute myocardial infarction. Circulation 2015;132:1880–1890.

173. Toldo S, Mezzaroma E, Tasselli BW, Van Sark F, Marchetti C, Voelkel NF, Abate A. Interleukin-1β blockade improves cardiac remodeling after myocardial infarction without interrupting the infammasome in the mouse. Exp Physiol 2019;104:734–745.

174. British National Formulary. ANAKINRA: British National Formulary. https://www.evidencedh.nhs.uk/formulary/bnf/current/10-musculoskeletal-and-joint-diseases/101-drugs-used-in-rheumatic-diseases-and-gout/1013-drugs-that-suppress-the-rheumatic-disease-process/cytokine-modulators/anakinra (28 June 2018, date last accessed).

175. Dhimolea E. Canakinumab. MAbs 2010;2:3–13.

176. Kurrelmeyer KM, Michael LH, Baumgarten G, Taffet GE, Peschon JJ, Swisssubramanian N, Ennnam ML, Mann DL. Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction. Proc Natl Acad Sci U S A 2000;97:5456–5461.

177. Harasui B, Bykerk V. Etanercept in the treatment of rheumatoid arthritis. Ther Clin Risk Manag 2007;3:99–105.

178. Schrotta Walker WC, Kral JB, Badhnya S, Assinger A. Aspirin and P2Y12 inhibitors in platelet-mediated activation of neutrophils and monocytes. Thromb Haemost 2015;114:478–489.

179. Solheim S, Arnesen H, Eikvar L, Hurlen M, Seljeflot I. Influence of aspirin on inflammatory markers in patients after acute myocardial infarction. Am J Cardiol 2003;92:843–845.

180. Kwak B, Mulhaupt F, Myt S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2007;13:389–1900.

181. Quinaglia e Silva JC, Munoz DB, Morato TN, Gurgel A, Macedo ACT, Sever P, Spotto AC. Effect of beta blockers (metoprolol or propranolol) on effect of simvastatin in lowering C-reactive protein in acute myocardial infarction. Am J Cardiol 2009;103:461–463.

182. Raimondo D, Di, Tuttolomondo A, Butta C, Miceli S, Licata G, Pinto A. Effects of ACE-inhibitors and angiotensin receptor blockers on inflammation. J Cardiovasc Med 2012;13:485–488.

183. Jernberg T, Haspold V, Henriksson M, Hjelm H, Thoursson M, Janson M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J 2015;36:1163–1170.

184. Traverse J, Henry TD, Peppine CJ, Willerson JT, Chugh AR, Yang PC, Zhao D, Ellis SR, Ford Jr, Perin EC, Penn MS, Hatzopoulos AK, Chambers JW, Baran K, Raveendran G, Gee AP, Taylor DA, Moye L, Ebert RF, Simari RD. The TIME Trial—Multicenter-disease-process/cytokine-modulators/anakinra (28 June 2018, date last accessed).

185. Bewtra M, Lewis JD. Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease. Expert Rev Clin Immunol 2010;6:621–631.

186. Ridker PM, Macfadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ, Ridker P. Long-term follow-up: effect of anakinra to prevent adverse cardiac remodeling after acute myocardial infarction: the ANAHEIM pilot study. Circulation 2015;1313:1880–1890.

187. Ridker PM, Macfadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ, Ridker P. Long-term follow-up: effect of anakinra to prevent adverse cardiac remodeling after acute myocardial infarction: the ANAHEIM pilot study. Circulation 2015;1313:1880–1890.
Klemdal TO, Medina F, Budaj A, Vida-Simiti L, Kobašava Z, Otasevic P, Pella D, Lainscak M, Seung K-B, Commerford P, Dellborg M, Donath M, Hwang JJ, Kultursay H, Flather M, Ballantyne C, Blazarian S, Chang W, East C, Everett B, Forgosh L, Glynn R, Harris B, Libby P, Ligueros M, Thuren T, Bohula E, Charmanthi B, Cheng S, Chou S, Danik J, McMahon G, Maron B, Ning MMing, Olenchock B, Pande R, Perlstein T, Pradhan A, Rost N, Singhal A, Taqueti V, Wei N, Burris H, Cioffi A, Dalseg AM, Ghosh N, Gralow J, Mayer T, Rugo H, Fowler V, Limaye AP, Cosgrove S, Levine D, Lopes R, Scott J, Thuren T, Ligueros M, Hilbert R, Tamesby G, Mickel C, Manning B, Woelske J, Tan M, Manfreda S, Ponce T, Kam J, Saini R, Banister K, Salik T, Nandy P, Tawfik R, O’Neil G, Manne S, Jirvankar P, Lal S, Nema D, Josi J, Collins R, Bailey K, Blumenthal R, Colhoun H, Gersh B, Glynn RJ. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet 2017;390:1833–1842.